{
    "clinical_study": {
        "@rank": "111133", 
        "acronym": "Match-101", 
        "arm_group": [
            {
                "arm_group_label": "Mitiglinide", 
                "arm_group_type": "Experimental", 
                "description": "Mitiglinide 10 mg three times a day, orally, for 12 weeks"
            }, 
            {
                "arm_group_label": "Acarbose", 
                "arm_group_type": "Active Comparator", 
                "description": "Acarbose 50 mg three times a day, orally, for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Mitiglinide, a benzylsuccinic acid derivative, exerts selective action on the ATP-dependent\n      K (KATP) channel  of pancreatic \u03b2-cells and reportedly possesses a stronger affinity to the\n      channel compared with other insulinotropic  sulphonylurea receptor ligands, namely\n      repaglinide and nateglinide. Preprandial administration of mitiglinide efficiently reduces\n      postprandial hyperglycemia and improves overall glycemic control.\n\n      This was a 12-week, open, randomized study for comparing Mitiglinide versus  Acarbose. The\n      purpose of this study is to evaluate the efficacy and safety of Mitiglinide vs Acarbose in\n      patients with type 2 diabetes mellitus."
        }, 
        "brief_title": "Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus", 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "Group I (Mitiglinide): Mitiglinide 10 mg three times a day, orally, for 12 weeks Group II\n      (Acarbose): Acarbose 50 mg three times a day, orally, for 12 weeks Total subjects: 248,\n      randomized to 2 groups at ratio of 1:1."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects aged between 18 and 70, regardless of gender\n\n          2. Subjects with type-2 diabetes mellitus diagnosed according to 1999 WHO criteria\n             within 5 years\n\n          3. Subjects who had not received insulin secretagogues, insulin sensitizers, incretin\n             mimetics or alpha-glucosidase inhibitors\n\n          4. Subjects whose fasting blood glucose [FBG] between7.0 and10.0 mmol/L and HbA1c ratio\n             is between 7.0% and 10.0%\n\n        Note: Incretin mimetics contain glucagon-like peptide 1 (GLP-1) receptor agonist\n        (including GLP-1 analogues) and dipeptidyl peptidase 4 inhibitors.\n\n        Exclusion Criteria:\n\n          1. Subjects with abnormal hepatic function whose aspartate transaminase (AST) and\n             alanine transaminase (ALT) are 2 times higher than the upper limits of normal (ULN)\n\n          2. Subjects with renal disfunction  whose plasma creatinine concentration are more than\n             1.1 ULN or positive urine protein\n\n          3. Subjects with severe heart disease, liver diseases, kidney disease and other serious\n             organic disease\n\n          4. Subjects who have chronic intestinal diseases associated with marked disorders of\n             digestion or absorption and may deteriorate as a result of increased gas formation in\n             the intestine (like Gastrocardiac Syndrome, severe hernia, intestinal obstruction,\n             intestinal ulcer and intestinal surgery)\n\n          5. Subjects with endocrine system diseases such as hyperthyroidism and cushing's\n             syndrome etc.\n\n          6. Subject is contraindicated or hypersensitivity to both experimental drugs or\n             comparator drugs\n\n          7. Subjects who participated in other clinical studies as subjects within 3 months\n             before this study\n\n          8. Female subjects who have been pregnant , lactating or without contraception in\n             childbearing potential\n\n          9. Subjects judged unfit for this study by investigators"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "248", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143765", 
            "org_study_id": "ZhongdaH-Match"
        }, 
        "intervention": [
            {
                "arm_group_label": "Mitiglinide", 
                "intervention_name": "Mitiglinide", 
                "intervention_type": "Drug", 
                "other_name": "FADI"
            }, 
            {
                "arm_group_label": "Acarbose", 
                "intervention_name": "Acarbose", 
                "intervention_type": "Drug", 
                "other_name": "PRECOSE"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acarbose", 
                "Mitiglinide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Mitiglinide", 
            "Acarbose", 
            "Type 2 Diabetes Mellitus"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "contact": {
                "email": "sunzilin1963@126.com", 
                "last_name": "Zilin Sun", 
                "phone": "+82-025-83262818"
            }, 
            "facility": {
                "address": {
                    "city": "Nanjing", 
                    "country": "China", 
                    "state": "Jiangsu"
                }, 
                "name": "Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, Southeast University"
            }, 
            "investigator": [
                {
                    "last_name": "Zilin Sun", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Yang Yuan", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open, Multi-center, Randomized Study to Evaluate the Efficacy and Safety of Mitiglinide Versus Acarbose in Patients With Type 2 Diabetes Mellitus in China", 
        "overall_contact": {
            "email": "sunzilin1963@126.com", 
            "last_name": "Zilin Sun", 
            "phone": "+83-025-83262818"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143765"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zhongda Hospital", 
            "investigator_full_name": "Zilin Sun", 
            "investigator_title": "Chief of Department of Endocrinology, Zhongda Hospital, Institute of Diabetes", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "23602502", 
            "citation": "Zhu Q, Tong Y, Wu T, Li J, Tong N. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis. Clin Ther. 2013 Jun;35(6):880-99. doi: 10.1016/j.clinthera.2013.03.020. Epub 2013 Apr 18. PubMed PMID: 23602502."
        }, 
        "secondary_outcome": [
            {
                "measure": "the change from baseline to the end of treatment in fasting blood glucose (FBG), postprandial blood glucose (PBG)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 4 weeks, 8 weeks, 12 weeks"
            }, 
            {
                "description": "Adverse events will be collected and followed in order to evaluate safety and tolerability", 
                "measure": "Number of Participants with Serious and Non-Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "description": "measured by Diabetes specific Quality of Life scale  (DSQL) at baseline and 12 weeks", 
                "measure": "the change from baseline to the end of treatment in Diabetes Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 weeks"
            }, 
            {
                "measure": "Treatment compliance", 
                "safety_issue": "No", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "description": "measured by  Diabetes Treatment Satisfaction Questionnaire (DTSQs) at 12 weeks", 
                "measure": "Diabetes Treatment Satisfaction", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Zhongda Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhongda Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}